Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the remaining countries covered in this report.
Clarivate Epidemiology’s PH forecast will answer the following questions:
Of all people diagnosed PH, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PH over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following PH patient populations:
Diagnosed prevalent cases of PH.
Diagnosed prevalent cases of PH by subtype.
Diagnosed prevalent cases of PAH by etiology.
Diagnosed prevalent cases of PAH by NYHA severity classification scheme.
Diagnosed prevalent cases of PH associated with LHD.
Diagnosed prevalent cases of PH associated with LHD by etiology subtypes.
Diagnosed prevalent cases of PH associated with chronic lung disease.
Diagnosed prevalent cases of PH associated with chronic lung disease by comorbid lung condition.
Diagnosed prevalent cases of CTEPH.
Diagnosed prevalent cases of CTEPH by surgical intervention.
Diagnosed prevalent cases of PH caused by miscellaneous factors.
Diagnosed prevalent cases of PH by drug-treatment.
Literature review (studies included in / excluded from the analyses of pulmonary hypertension)
Diagnosed prevalence of pulmonary hypertension
Pulmonary hypertension subtypes by etiology
Pulmonary arterial hypertension subtypes by etiology
Pulmonary arterial hypertension subtypes by New York Heart Association functional classification scheme
Pulmonary hypertension due to left heart disease subtypes by etiology
Pulmonary hypertension due to chronic lung disease by comorbid lung condition
Chronic thromboembolic pulmonary hypertension subtypes defined by surgical intervention
Drug-Treated Prevalent Cases
Risk / protective factors applied to disease forecast models
Sunali D. Goonesekera, S.M.
Sunali D. Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.